Oculis Holding Ag (OCS)
NASDAQ:OCS
Want to see OCS full AI Analyst Report?
OCS Stock Chart & Stats
$27.46
$0.20(1.10%)
At close: 4:00 PM EST
$27.46
$0.20(1.10%)
Day’s Range― - ―
52-Week Range$10.52 - $34.48
Previous CloseN/A
Volume95.89K
Average Volume (3M)984.50K
Market Cap
$641.44M
Enterprise Value$453.91M
Total Cash (Recent Filing)$221.37M
Total Debt (Recent Filing)$2.24M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Aug 06, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding57,169,476
10 Day Avg. Volume809,745
30 Day Avg. Volume984,500
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue900.61
Enterprise Value/Gross Profit-31.17
Enterprise Value/Ebitda-4.82
Forecast
1Y Price Target
$38.30Price Target Upside39.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$787.01K
Bulls Say, Bears Say
Bulls Say
Low Leverage & Strong Balance SheetVery low leverage and a sizable equity base provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing risk, supports continued R&D spend and partnerships, and gives management runway to advance trials without immediate debt pressures over the next 2–6 months.
Substantial Short-term LiquidityMaterial cash plus large short-term financial assets underpin operational continuity and trial funding. This liquidity mix reduces the immediacy of fundraising needs, enabling milestone-driven clinical programs and measured capital deployment over a multi-month horizon without forcing dilutive transactions immediately.
Board Expertise And Capital Flexibility IncreasedAdding a veteran biotech CFO with U.S. capital-markets experience strengthens governance and fundraising capability. Simultaneously authorizing capital instruments and treasury shares enhances the company's strategic flexibility to execute financings, incentive programs, or partnerships in line with long-term development goals.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow at roughly -$62M TTM indicates ongoing funding consumption from R&D and operations. Without a material revenue inflection or spending reduction, this burn profile necessitates future financing, constraining strategic options and increasing dilution risk over the medium term.
Deep Losses, Minimal RevenueVery limited revenue alongside approximately $95M net loss shows lack of commercialization and negative operating leverage. The company remains dependent on progressing clinical assets to value inflection points; until revenues scale, losses will pressure reserves and require external funding to sustain operations.
Authorized Equity Issuance & Dilution RiskAGM approvals expanding registered shares, conditional capital and treasury issuance signal readiness to access equity markets. Given ongoing losses and cash burn, these measures increase the probability of dilution for existing shareholders as management retains options to raise capital to fund clinical programs and corporate needs.
Oculis Holding News
OCS FAQ
What was Oculis Holding Ag’s price range in the past 12 months?
Oculis Holding Ag lowest stock price was $10.52 and its highest was $34.48 in the past 12 months.
What is Oculis Holding Ag’s market cap?
Oculis Holding Ag’s market cap is $641.44M.
When is Oculis Holding Ag’s upcoming earnings report date?
Oculis Holding Ag’s upcoming earnings report date is Aug 06, 2026 which is in 47 days.
How were Oculis Holding Ag’s earnings last quarter?
Oculis Holding Ag released its earnings results on May 11, 2026. The company reported -$0.621 earnings per share for the quarter, missing the consensus estimate of -$0.507 by -$0.114.
Is Oculis Holding Ag overvalued?
According to Wall Street analysts Oculis Holding Ag’s price is currently Undervalued.
Does Oculis Holding Ag pay dividends?
Oculis Holding Ag does not currently pay dividends.
What is Oculis Holding Ag’s EPS estimate?
Oculis Holding Ag’s EPS estimate is -0.5.
How many shares outstanding does Oculis Holding Ag have?
Oculis Holding Ag has 57,169,476 shares outstanding.
What happened to Oculis Holding Ag’s price movement after its last earnings report?
Oculis Holding Ag reported an EPS of -$0.621 in its last earnings report, missing expectations of -$0.507. Following the earnings report the stock price went down -6.861%.
Which hedge fund is a major shareholder of Oculis Holding Ag?
Currently, no hedge funds are holding shares in OCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oculis Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.30 (39.48% Upside)
$38.30 (39.48% Upside)
Blogger Sentiment
Bullish
OCS Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.40%
12-Months-Change
Fundamentals
Return on Equity
-57.09%
Trailing 12-Months
Asset Growth
31.58%
Trailing 12-Months
Company Description
Oculis Holding Ag
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
OCS Stock 12 Month Forecast
Average Price Target
$38.30
▲(39.48% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Spyre Therapeutics
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Upstream Bio, Inc.
―
Ownership Overview
―
Insiders
1.58% Mutual Funds
26.35% Other Institutional Investors
71.83% Public Companies and
Individual Investors